235 related articles for article (PubMed ID: 30251024)
1. ASO Author Reflections: Long-Term Outcomes After R0 Resection of Colorectal Peritoneal Metastasis.
Shida D
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):832-833. PubMed ID: 30251024
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Cytoreductive Surgery for Colorectal Peritoneal Metastases-Is It Time to Audit Our Results?
García-Fadrique A
Ann Surg Oncol; 2022 Jan; 29(1):203-204. PubMed ID: 34435299
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Toward Improved Selection of Patients for Cytoreduction and HIPEC: Identification of Prognostic Factors for Patients with Colorectal Peritoneal Metastases.
Sluiter NR; Tuynman JB
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):840-841. PubMed ID: 30302638
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Peritoneal Metastases from Endometrial Cancer.
Sammartino P; Cornali T
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):882-883. PubMed ID: 30288653
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Achieving Long-Term Survival in Patients with Peritoneal Carcinomatosis of Colorectal Origin.
Sarfaty E; Cohen NA
Ann Surg Oncol; 2024 Mar; 31(3):2010-2011. PubMed ID: 38063982
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Lee ZJ; Teo CCM
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):757-758. PubMed ID: 30374919
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Biopsychosocial Late Effects are Frequent and Negatively Impact Quality of Life Following Curatively Intended Surgery for Colorectal and Appendiceal Cancer with Peritoneal Metastases.
Balachandran R; Thaysen HV; Christensen P; Zachariae R; Iversen LH
Ann Surg Oncol; 2024 Mar; 31(3):1696-1697. PubMed ID: 38071710
[No Abstract] [Full Text] [Related]
8. Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy.
Shida D; Tsukamoto S; Ochiai H; Kanemitsu Y
Ann Surg Oncol; 2018 Jan; 25(1):173-178. PubMed ID: 29063295
[TBL] [Abstract][Full Text] [Related]
9. ASO Author Reflections: R0 Resection and Targeted Therapy for Colorectal Peritoneal Metastasis.
Shida D
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):842-843. PubMed ID: 30324473
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Postoperative Inflammatory Markers as a Surveillance Tool in Colorectal Peritoneal Carcinomatosis.
Tan JW; Thiagarajan S; Zhou S; Tan QX; Hendrikson J; Ng WH; Ng G; Liu Y; Wong JSM; Tan GHC; Soo KC; Teo MCC; Chia CS; Ong CJ
Ann Surg Oncol; 2021 Oct; 28(11):6636-6637. PubMed ID: 33733373
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Ang JJ; Sundar R; Kim G; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2022 Dec; 29(13):8606-8607. PubMed ID: 36192514
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: Is There Still a Role for Intraperitoneal Oxaliplatin for Colorectal Peritoneal Metastases?
Taibi A; Hübner M; Eveno C; Dumont F; Glehen O; Sgarbura O
Ann Surg Oncol; 2022 Aug; 29(8):5252-5253. PubMed ID: 35355127
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma.
Chouliaras K; Votanopoulos KI
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):770-771. PubMed ID: 30421064
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Cisplatin- and Adrenaline-Based Intraperitoneal Chemotherapy Protocol for Ovarian Peritoneal Carcinosis: New Perspectives?
Paquette B
Ann Surg Oncol; 2022 May; 29(5):3335-3336. PubMed ID: 35072865
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis.
Baumgartner JM; Kurzrock R
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):772-773. PubMed ID: 30421042
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: Which is the Optimal Preoperative Systemic Chemotherapy Regimen for Patients with Peritoneal Metastases from Colorectal Cancer?
Kepenekian V; Kefleyesus A; Passot G; Rousset P; Benzerdjeb N; You B; Peron J; Glehen O
Ann Surg Oncol; 2023 Jun; 30(6):3316-3317. PubMed ID: 36752969
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: The Effect of Bowel Resection During Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy on Bowel-Related Quality of Life.
Bayat Z; Govindarajan A
Ann Surg Oncol; 2020 Jan; 27(1):132-133. PubMed ID: 31602581
[No Abstract] [Full Text] [Related]
18. ASO Author Reflections: Pathologic Classification of Pseudomyxoma Peritonei.
Baratti D
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):844-845. PubMed ID: 30324483
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Fragmented Care in Patients with Peritoneal Metastases.
Vierra M; Bansal VV; Shergill A; Turaga KK; Eng OS
Ann Surg Oncol; 2024 Jan; 31(1):655-656. PubMed ID: 37803088
[No Abstract] [Full Text] [Related]
20. Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
Bhandare M; Patil P; Pai V; Bhamre R; Engineer R; Ostwal V; Saklani A
Clin Colorectal Cancer; 2017 Jun; 16(2):e1-e6. PubMed ID: 27670895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
